Takayuki Katsube
Overview
Explore the profile of Takayuki Katsube including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang C, Yu S, Li S, Wu X, Wei Q, He J, et al.
Adv Ther
. 2025 Mar;
PMID: 40080239
Introduction: We aim to evaluate the safety and pharmacokinetic (PK) properties of cefiderocol in Chinese participants, following single and subsequent multiple administrations of 2 g q8h with 3-h intravenous infusion,...
2.
Sasaki T, Katsube T, Hayato S, Yamaguchi S, Tanaka J, Yoshimatsu H, et al.
J Pharmacokinet Pharmacodyn
. 2025 Jan;
52(1):10.
PMID: 39762622
Model-informed drug development (MIDD) is an approach to improve the efficiency of drug development. To promote awareness and application of MIDD in Japan, the Data Science Expert Committee of the...
3.
Bradley J, Orchiston E, Portsmouth S, Ariyasu M, Baba T, Katsube T, et al.
Pediatr Infect Dis J
. 2024 Sep;
44(2):136-142.
PMID: 39230271
Background: Multidrug-resistant Gram-negative bacterial infections are increasing globally in neonates, infants and children; antibiotic options are limited. Methods: This international, multicenter, open-label phase 2 study, investigated the pharmacokinetics, safety and...
4.
Yamaguchi D, Katsube T, Wajima T
Pharmacol Res Perspect
. 2024 Aug;
12(5):e70001.
PMID: 39180172
When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size...
5.
Katsube T, Kezbor S, Shimizu R, Kubota R
Infect Dis Ther
. 2024 Aug;
13(9):2103.
PMID: 39136875
No abstract available.
6.
Katsube T, Kezbor S, Shimizu R, Kubota R
Infect Dis Ther
. 2024 Mar;
13(3):597-607.
PMID: 38460082
Introduction: Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19. Since urinary recovery of ensitrelvir ranged from 12.9%...
7.
Flamm S, Peck-Radosavljevic M, Fukuhara T, Bentley R, Katsube T, Ochiai T, et al.
Adv Ther
. 2022 Jul;
39(9):4285-4298.
PMID: 35904722
Introduction: Patients with thrombocytopenia and chronic liver disease are at increased risk of bleeding during invasive procedures due to low platelet counts. Lusutrombopag, an orally active thrombopoietin receptor agonist, increases...
8.
Wenzler E, Butler D, Tan X, Katsube T, Wajima T
Clin Pharmacokinet
. 2022 Jun;
61(7):1069.
PMID: 35661333
No abstract available.
9.
Wenzler E, Butler D, Tan X, Katsube T, Wajima T
Clin Pharmacokinet
. 2021 Nov;
61(4):539-552.
PMID: 34792787
Background: The need for continuous renal replacement therapy (CRRT) in critically ill patients with serious infections is associated with clinical failure, emergence of resistance, and excess mortality. These poor outcomes...
10.
Kawaguchi N, Katsube T, Echols R, Wajima T, Nicolau D
J Clin Pharmacol
. 2021 Oct;
62(5):670-680.
PMID: 34648652
Cefiderocol is a siderophore cephalosporin for the treatment of infections caused by gram-negative bacteria including carbapenem-resistant strains. The aim of this study was to develop an intrapulmonary pharmacokinetic (PK) model...